ArticleCureus2025
A Sight-Threatening Genetic Disorder: A Rare Ocular Manifestation of Von Hippel-Lindau Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Hippel-Lindau (VHL) syndrome is a rare inherited genetic disorder caused by mutations in the VHL tumor suppressor gene on chromosome 3. It leads to the development of multiple benign and malignant tumors in various organs. This report details a rare case of ocular VHL syndrome in an 11-year-old girl. She presented with progressive vision loss in her right eye and a family history of blindness and brain tumors. On examination, her right eye showed almost total retinal detachment and severe vision impairment, while her left eye had multiple retinal hemangioblastomas with subretinal fluid but preserved visual acuity. The patient was diagnosed with VHL syndrome and treated with laser photocoagulation for the retinal hemangioblastomas. After several treatments, her vision in the left eye remained stable at the six-month follow-up. While VHL syndrome typically presents in late teens to early adulthood, this case highlights the importance of early diagnosis and continuous screening, especially given the condition's genetic nature and potential for multiorgan involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.